CervoMed reports third quarter 2026 financial results
Net loss was $5.9 million versus $7.7 million a year earlier, with $19.6 million in cash funding operations through the third quarter of 2027.
See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing treatments for age-related brain disorders
cervomed.comLast updated
In short: CervoMed reported a $5.9 million Q3 loss and sought a partner for neflamapimod's Phase 3 DLB program.
Net loss was $5.9 million versus $7.7 million a year earlier, with $19.6 million in cash funding operations through the third quarter of 2027.
Results show reduced neurofilament light levels over 12 weeks in nfvPPA patients at the ISFTD meeting. Further data is expected later this year.
The company introduces a 50 mg oral tablet for neflamapimod, securing FDA removal of exposure limits to enable a twice-daily dosing regimen.
The twelve-week biomarker findings will be presented at the ISFTD Annual Meeting in October to support ongoing neurodegenerative disease development.
CervoMed Inc. has released its results for the third quarter and the nine months ended September 30, 2026. In the third quarter, the company...
On October 12, 2026, CervoMed reported initial 12-week biomarker data from the open-label portion of its Phase 2a trial of neflamapimod in nonfluent variant primary...
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) ...
CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple. On March...
Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CervoMed and other trending companies.